Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis

Cell Cycle

Volumn 3, Issue 10, 2004, Pages 1240-1242

  Zhu, Ping ^a,d,e   Huber, Evamaria ^b   Kiefer, Franz ^b   Göttlicher, Martin ^b,c  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CMM East   (United States)

Author keywords

Apoptosis; Cancer treatment; Cell cycle; Colon cancer; HDAC inhibitors; Histone deacetylases; Myeloid leukemia

Indexed keywords

APC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 9; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

APOPTOSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL STRAIN HT29; COLON CANCER; ENZYME SPECIFICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEART; HUMAN; MYELOID LEUKEMIA; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRESS; TRANSCRIPTION REGULATION; WILD TYPE;

EID: 13944284147     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.10.1195     Document Type: Review

References (18)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002; 12:142-8.
3. Krämer OH, Göttlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001; 12:294-300.
4. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9:322-32.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
6. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: Versatile regulators. Trends Genet 2003; 19:286-93.
7. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21:2672-81.
8. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110:479-88.
9. Fodde R. The multiple functions of tumour suppressors: It's all in APC. Nat Cell Biol 2003; 5:190-2.
10. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
11. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004; 5:455-63.
12. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3:344-51.
13. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5:245-53.
14. WAf1 is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95:6791-6.
15. Della Ragione F, Criniti V, Della Pietra V, Borriello A, Oliva A, Indaco S, Yamamoto T, Zappia V. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 2001; 499:199-204.
16. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20:6969-78.
17. Phiel CJ, Zhang F, Huang EY, Guenthor MG, Lazar MH, Klein PS. Histone deacetylase is a direct target of of valproic acide, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem 2001; 276:36734-41.
18. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93:7950-4.